EKF Diagnostics Holdings plc (EKF.L)
EKF.L Stock Price Chart
Explore EKF Diagnostics Holdings plc interactive price chart. Choose custom timeframes to analyze EKF.L price movements and trends.
EKF.L Company Profile
Discover essential business fundamentals and corporate details for EKF Diagnostics Holdings plc (EKF.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
4 Jan 2000
Employees
303.00
Website
https://www.ekfdiagnostics.comCEO
Gavin Joseph Jones
Description
EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; DiaSpect Hemoglobin T analyzer; Hemo Control, a hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers' milk; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company provides clinical chemical analyzers, such as Beta-hydroxybutyrate for monitoring ketosis; Glycated Albumin; Glycated Serum Protein; Nitro-tab Ketone tablets; and Procalcitonin marker for bacterial infection and sepsis, as well as reagents, calibrators, standards, and controls. Additionally, it offers RaPET Serology immunoassay kits; QuStick Strep A for Strep A infection treatment; Altair 240, a chemistry analyzer; Excel, a semi-automated chemistry analyzer; Micro 12, a micro centrifuge for clinical, molecular, and bacteriological applications; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; Uri-Trak 120 urine analyzer; and kits and other services related to COVID-19, as well as contract manufacturing solutions to third-party businesses and laboratory services. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.
EKF.L Financial Timeline
Browse a chronological timeline of EKF Diagnostics Holdings plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 23 Mar 2026
Upcoming earnings on 15 Sept 2025
Earnings released on 25 Mar 2025
EPS came in at £0.01 surpassing the estimated £0.01 by +84.00%, while revenue for the quarter reached £24.98M, beating expectations by +0.21%.
Earnings released on 17 Sept 2024
EPS came in at £0.00 falling short of the estimated £0.01 by -9.00%, while revenue for the quarter reached £25.21M, missing expectations by -3.03%.
Earnings released on 20 Mar 2024
EPS came in at £0.01 falling short of the estimated £0.01 by -10.90%, while revenue for the quarter reached £25.74M, missing expectations by -52.92%.
Dividend declared on 2 Nov 2023
A dividend of £1.20 per share was announced, adjusted to £1.20. The dividend was paid on 1 Dec 2023.
Earnings released on 26 Sept 2023
EPS came in at -£0.00 falling short of the estimated £0.01 by -112.74%, while revenue for the quarter reached £26.87M, beating expectations by +2.17%.
Earnings released on 28 Mar 2023
EPS came in at -£0.03 falling short of the estimated £0.01 by -481.27%, while revenue for the quarter reached £29.16M, missing expectations by -48.56%.
Earnings released on 30 Jun 2022
EPS came in at £0.00 falling short of the estimated £0.01 by -63.83%, while revenue for the quarter reached £37.47M, missing expectations by -0.08%.
Dividend declared on 29 Mar 2022
A dividend of £1.20 per share was announced, adjusted to £1.20. The dividend was paid on 1 Dec 2022.
Earnings released on 31 Dec 2021
EPS came in at £0.01 falling short of the estimated £0.02 by -30.99%, while revenue for the quarter reached £43.28M, beating expectations by +1.95%.
Earnings released on 30 Jun 2021
EPS came in at £0.02 falling short of the estimated £0.02 by -8.90%, while revenue for the quarter reached £38.56M, missing expectations by 0.00%.
Dividend declared on 30 Mar 2021
A dividend of £1.10 per share was announced, adjusted to £1.10. The dividend was paid on 1 Dec 2021.
Earnings released on 31 Dec 2020
EPS came in at £0.02 falling short of the estimated £0.03 by -42.11%, while revenue for the quarter reached £38.93M, beating expectations by +2.45%.
Dividend declared on 7 Apr 2020
A dividend of £1.00 per share was announced, adjusted to £1.00. The dividend was paid on 1 Dec 2020.
EKF.L Stock Performance
Access detailed EKF.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.